Hong Kong-based HUTCHMED (China) Limited is making strides in the field of targeted therapeutics and immunotherapies for the treatment of cancer and immunological diseases. Its portfolio of drugs includes Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC), Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors, and Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors. In addition, the company has developed a spleen tyrosine kinase inhibitor, HMPL-523, for the treatment of hematological cancers and certain chronic immune diseases, as well as inhibitors for EZH2, hematological malignancies, gliomas, and solid tumors. HUTCHMED (China) Limited has collaboration agreements with several major international pharma and biotech companies, including AstraZeneca, Lilly, and BeiGene, among others. The company was incorporated in 2000 and is headquartered in Central, Hong Kong, having changed its name from Hutchison China MediTech Limited to HUTCHMED (China) Limited in May 2021.
HUTCHMED (China)'s ticker is HCM
The company's shares trade on the NASDAQ stock exchange
They are based in Central, Hong Kong
There are 501-1000 employees working at HUTCHMED (China)
It is hutch-med.com
HUTCHMED (China) is in the Healthcare sector
HUTCHMED (China) is in the Biotechnology industry
The following five companies are HUTCHMED (China)'s industry peers: